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Complications of pregnancy have been found to be related with thrombophilic polymorphisms that explain about 30% of obstetric
complications. We evaluated the angiotensin converting enzyme (ACE) and the angiotensin type 1 receptor (AT1R) gene
polymorphisms in the renin±angiotensin system (RAS) as possible risk factors for fetal loss. Fifty-nine women with a history of
three or more ®rst-trimester fetal losses and 70 healthy women with a history of normal pregnancies were enrolled in this study.
Thrombophilic factors, ACE insertion/deletion (I/D) and AT1R A1166C polymorphisms, prothrombin G20210A and factor V
Leiden mutations were analyzed. At univariate and multivariate analysis, a signi®cant association between ACE DD and AT1R CC
genotype and fetal loss was observed. The effect of the ACE DD genotype on the risk of fetal loss was higher in AT1R C allele
carriers. The prevalence of hyperhomocysteinemia (Hcy) (de®ned as baseline plasma levels higher than the 95% percentile; cut-off,
10.5 ìmol/l per l) was signi®cantly higher in women with fetal loss, and an association between Hcy and fetal loss was detected. All
patients showed normal antithrombin, protein C, protein S, and plasminogen activator inhibitor-1 (PAI-1) values. The presence of
one risk factor not associated with others was found in 33 out of 59 patients (56%); ACE DD genotype was the most prevalent risk
factor. Our results identify new possible predictive markers for fetal loss in RAS polymorphisms and Hcy. Large-scale studies are
warranted to attribute clinical relevance to these polymorphisms as risk factors for complicated pregnancies. Blood Coagul
Fibrinolysis 11:657±662 # 2000 Lippincott Williams & Wilkins.
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Introduction
Obstetrical complications such as severe pre-eclamp-
sia, fetal growth retardation, stillbirth and fetal loss
contribute to maternal and fetal morbidity and
mortality. The causes have not been completely
elucidated, but they have recently been associated
with abnormal placental vasculature [1] and distur-
bances of hemostasis [2]. The renin±angiotensin
system (RAS) is one of the main factors regulating
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blood pressure, ¯uid and electrolyte balance. Placen-
tal and fetal membranes are important production
sites of the angiotensin converting enzyme (ACE)
and angiotensinogen (AGT), and contain high con-
centrations of angiotensin II receptors [3]. In addi-
tion, angiotensin II may increase the production and
secretion of the plasminogen activator inhibitor-1
(PAI-1) by endothelial cells [4]. ACE may also
increase platelet function because ACE inhibitors
have been shown to reduce platelet aggregation in
humans [5].
An insertion/deletion (I/D) polymorphism in the
ACE gene has been associated with serum ACE
activities: subjects with DD ACE genotype had
higher levels than those with the ACE II genotype,
and intermediate levels were observed in heterozy-
gote ID [6]. In pregnancy-induced hypertension,
elevated serum ACE activity was found [7±9], but
no effect of ACE gene polymorphism on pregnancy
outcome or the incidence of pregnancy-induced
hypertension has been found in Caucasian women.
In a series of Caucasian women with pregnancy-
induced hypertension, a signi®cant association of
pre-eclampsia with the AGT M235T polymorphism
has been observed. No data are available on the
A1166C polymorphism in the gene encoding for the
angiotensin II type 1 receptor (AT1R).
A higher prevalence of thrombophilic polymorph-
isms such as factor V (FV) Leiden mutation and
factor II (FII) G20210A mutation has been reported
in women with fetal loss, pre-eclampsia, abruptio
placentae and fetal growth retardation [10,11]; how-
ever, genetic thrombophilic polymorphisms account
for about 30% of obstetrical complications [12].
In this study, we have evaluated RAS ACE and
AT1R polymorphisms as possible risk factors for
pathological pregnancies and for their possible con-
tribution to the occurrence of fetal loss.
Materials and methods
From April 1998 to March 1999, we enrolled 59
consecutive women with a history of fetal loss
referred to the Prenatal Medicine Unit of the
University of Florence. Women ful®lled the follow-
ing inclusion and exclusion criteria. Inclusion criter-
ia were three or more ®rst-trimester (7±12 weeks of
gestation) fetal losses. All were in good general
health without previous history of venous or arterial
thromboembolic disease, fetal growth retardation
and abruptio placentae. The exclusion criteria were
hypertension, previous pre-eclampsia, diabetes mel-
litus or thyroid dysfunction, the presence of
congenital malformations or chromosomal abnor-
malities in the fetus, recent cytomegalovirus infec-
tion or drug abuse during pregnancy and essential
thrombocytemia [13].
They all underwent a thorough investigation that
was negative for potential causes of fetal demise
including fasting glucose, basal follicle stimulating
hormone (FSH), luteinizing hormone (LH) and
estradiol levels on day 3 of a natural cycle, thyroid-
stimulating hormone (TSH) and prolactin levels, and
antinuclear factor. Screening tests for antiphospholi-
pid antibodies included lupus anticoagulant sensitive
activated antithromboplastin time, thromboplastin
titration index, diluted Russel Viper Venom test, and
immunoglobulin (Ig)G and IgM anticardiolipin and
antiâ2-glycoprotein I. If one of these assays was
positive, the patient was not included in the study
The control group consisted of 70 healthy women
matched for age, gravidity and smoking habits with
a history of normal pregnancies.
All the subjects of the patient and control groups
were Caucasian women from Central Italy (Tus-
cany). Personal and familial history of thromboem-
bolic disease was determined by interviewing
patients and controls. Both cases and controls were
not pregnant at the time of investigation, and were
not taking oral estroprogestinic preparations during
the study. Six out of 59 patients had taken the pill
before the index pregnancy. Informed consent was
obtained in all cases and controls.
Peripheral venous blood samples were collected
from the antecubital vein, with minimal stasis, in
vacutainer tubes containing 0.129 mol/l sodium cit-
rate, the ®nal blood/anticoagulant ratio being 9 : 1.
The samples were centrifuged at 600 3 g for 10 min
at 48C, and the supernatant was drawn off and
immediately stored at ÿ808C until analysis.
Mutations of the FV and FII gene were analysed
as previously described [14,15]. The FV gene muta-
tion was detected by polymerase chain reaction
(PCR) ampli®cation of genomic DNA followed by
digestion with the restriction enzyme Mnl I. The
G20210A mutation of FII gene was detected by
PCR ampli®cation with a mutagenic primer: the
ampli®ed fragment was digested by Hind III.
Antithrombin (AT) and protein C (PC) activities
were determined with an Electra 1000C coagulation
analyser using the chromogenic commercial kit
(Antithrombin III, Protein C; DADE, DuÈ dingen,
Switzerland). The normal range was 80±120% for
AT and 60±130% for PC. Protein S (PS) activity
was measured by the clotting method with an ACL
300 Research coagulation analyser (Instrumentation
Laboratory Company, Milan, Italy) using a com-
mercial kit (Protein S; Instrumentation Laboratory).
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The normal range was 55±130%. PAI-1 activity
(control range, 3±15 IU/ml) was determined accord-
ing to Chmielewska et al. [16], using a commercial
kit (Spectrolyse (®brin); Bio-Pool, Umea, Sweden).
The plasma levels of total homocysteine (free and
protein bound) were determined by high-perform-
ance liquid chromatography (LKB 2248 pump;
Pharmacia, Uppsala, Sweden) and ¯uorescence de-
tection (Waters 474, Italy Waters, Vimodrone (MI)
Italy). Median and range of control women were 7.5
and 3±15 ìmol/l per l, respectively.
ACE and AT1R polymorphisms were analyzed
after genomic DNA extraction from peripheral
blood leukocytes using a QIAmp Blood Kit (QIA-
GEN, Hilden, Germany). The ACE I/D poly-
morphism was genotyped according to Rigat et al.
[17]. DNA was ampli®ed with 5% dimethylsulf-
oxide (DMSO) in the reaction mixture at an anneal-
ing temperature of 608C in order to reduce the
incidence of mistyping ID as DD. Moreover, each
DD genotype was subjected to a second PCR
ampli®cation without the 5% DMSO at an anneal-
ing temperature of 678C and using a primer pair that
recognizes the insertion-speci®c sequence. These
modi®cations were made to reduce underestimation
of heterozygotes [18]. The A1166C polymorphism
of the AT1R gene was identi®ed by PCR ampli®ca-
tion and restriction fragment length polymorphism
analysis, using primers and PCR conditions as
described by Katsuja et al. [19].
Statistical analysis
Statistical analysis was performed by using the
program Statistica 6.0 (StatSoft Italia s.r.l., Vigonza
(Padova) Italy) for IBM. The ACE and AT1R allele
and genotype frequencies in patients and controls
were obtained by direct count. The genotype dis-
tribution and allele frequencies between groups were
compared by the ÷2 test. Association between
variables was tested using Fisher's exact test or the
÷2 test. The estimate of odds ratios (OR) was
obtained by univariate regression analysis. Multiple
regression analysis was used to evaluate the in¯u-
ence of ACE, AT1R, FV genotype and homocys-
teine levels on the occurrence of fetal loss. The
Hardy±Weinberg equilibrium for genotype distribu-
tion was estimated by the ÷2 test. P , 0.05 was
considered statistically signi®cant.
Results
The characteristics of patients and controls are
presented in Table 1. The ACE and AT1R genotype
distribution was compatible with the Hardy±Wein-
berg equilibrium. The genotype and allele frequen-
cies of RAS genes are shown in Table 2.
ACE D allele frequency was signi®cantly
(P  0.013) higher among women with fetal loss
than in the control group (65 versus 50%). A
signi®cant association between the ACE DD geno-
type and pregnancy loss was observed [OR(DD/
ID  II)  2.26, 95% con®dence interval (CI) 
1.09±4.67; P  0.03]. The difference of ACE I/D
genotype distribution between cases and controls
was not statistically signi®cant (P  0.07).
The AT1R C allele frequency was higher in
women with fetal loss (40 versus 28%; P  0.04),
and the genotype distribution was signi®cantly dif-
ferent between cases and controls (P  0.005). An
association between AT1R CC genotype and fetal
loss [OR(CC/AC  AA)  5.62, 95% CI  1.75±
18.08; P  0.002] was observed.
The effect of the ACE DD genotype on the risk
of fetal loss was higher in AT1R C allele carriers.
The OR for fetal loss associated with the ACE DD
genotype varied from 1.69 (95% CI  0.57±5.05;
P  0.34) in subjects without the C allele (AA
Table 1. Characteristics of study groups
Patients (n  59) Controls (n  70)
Age (years) 31 (23±40) 32.5 (21±41)
Gravidity 3 (3±5) 2 (2±5)
Smoker (%) 14 15
Values represent the median, with the range in parentheses.
Table 2. Distribution of renin±angiotensin system genotypes and
allele frequencies
Patients
(n  59)
Controls
(n  70) P value
ACE genotype
DD 28 20 0.07
ID 21 30
II 10 20
ACE allele frequency
D 0.65 0.50 0.013
I 0.35 0.50
AT1R genotype
CC 15 4 0.005
AC 17 31
AA 27 35
AT1R allele frequency
C 0.40 0.28 0.04
A 0.60 0.72
ACE, Angiotension converting enzyme; AT1R, angiotensin type
1 receptor.
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homozygotes) to 2.81 (95% CI  1.03±7.61;
P  0.04) in AT1R C allele carriers (AC heterozy-
gotes and CC homozygotes).
Six out of 59 (10%) women with fetal loss were
positive for FV Leiden mutation (heterozygotes or
homozygotes). The prevalence of FV Leiden tended
to be higher in patients than in controls, although
this did not make statistical signi®cance (Fisher
exact test; P  0.14) (Table 3). No difference was
found in the prevalence of either FII G20210A
mutation or PC, PS and AT de®ciencies between
patients and controls (Table 3).
High PAI-1 levels were seen in 6% of controls
and in 10% of patients. The difference in percentage
of high PAI-1 levels between controls (6%) and
patients (10%) was not statistically signi®cant (Fish-
er's exact test; P  0.51). No signi®cant association
was found between ACE DD and AT1R CC
genotype and PAI-1 plasma levels (Fisher's exact
test; P  1.00 and P  1.00, respectively).
Twelve out of 59 patients (20%) had homocys-
teine plasma levels higher than the 95% percentile.
We observed a signi®cant difference in the preva-
lence of hyperhomocysteinaemia between women
with pregnancy loss and control subjects (Fisher's
exact test; P  0.016) (Table 3), and an association
between hyperhomocysteinemia and fetal loss
[OR  4.21, 95% CI  1.28±13.88; P  0.02] was
detected.
In 14 out of 59 patients and in 31 out of 70
controls, none of the tested risk factors was found.
The presence of one risk factor not associated with
others was found in 33 out of 59 patients (56%);
ACE DD genotype was the most prevalent risk
factor. Figure 1 reports the number of patients with
each of several different risk factors, singly and in
combination.
By multiple regression analysis, ACE DD and
AT1R CC genotype and hyperhomocysteinemia
were found to be independent risk factors for fetal
loss (Table 4).
Discussion
This study is the ®rst report demonstrating that
RAS gene polymorphisms are associated with ®rst-
trimester fetal loss. ACE DD and AT1R CC
genotypes account for more than 50% of fetal loss,
whereas a thrombophilic condition accounts for
about 10% and hyperhomocysteinemia for 20%.
However, we observed that the AT1R C allele
increases the risk associated with the ACE DD
genotype, showing a synergistic effect on the occur-
rence of fetal loss, as previously described for
coronary disease [20,21].
Tamura et al. [7] evaluated the role of ACE I/D
polymorphism in pre-eclampsia, but the ACE DD
genotype was not found to be a risk factor for
pregnancy-induced hypertension. In this study, we
found not only that the ACE gene polymorphism
plays a signi®cant role in the risk of ®rst-trimester
fetal loss, but also that a polymorphism in the gene
encoding for angiotensin II type 1 receptor is
associated with the risk of fetal loss. The multiple
regression analysis provided evidence of the ACE
DD and AT1R CC genotypes as independent pre-
dictors of fetal loss.
The RAS plays an important role in the regulation
Table 3. Risk factors for fetal loss considered in the present study
Patients (n  59) Controls (n  70) P value
Factor V Leiden mutation 6 (10%) 2 (3%) 0.14
Hyperhomocysteinemia 12 (20%) 4 (6%) 0.016
Factor II G20210A mutation 1 (1.7%) 1 (1.4%) 1.00
Protein C de®ciency ± ±
Protein S de®ciency ± ±
Antithrombin de®ciency ± ±
20
15
10
5
1 risk factor
2 or more risk factors
2
6
8
17
FVL
CC
Hcy
DD
5 3 2 1 1
DD
1C
C
DD
1C
C1
FVL
DD
1H
cy
DD
1F
VL1
Hcy
CC1
Hcy
N
um
be
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Figure 1. Number of patients with one or more thromboembolic
risk factors. Hcy, Hyperhomocysteinemia; FVL, factor V Leiden.
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of vascular ®brinolytic balance [22]. The ACE is
strategically positioned to regulate the balance of the
®brinolytic elements by producing angiotensin II
[22]. Angiotensin II, in addition to being a potent
vasoconstrictor and to promoting smooth muscle
cell proliferation and intimal thickening, may in-
crease plasma PAI-1 levels in humans [23]. This
latter effect might constitute a link between the RAS
and vascular placental occlusion, although in the
present study we observed high plasma PAI-1 levels
in few patients. A further mechanism by which
ACE can in¯uence an occlusive tendency in placen-
tal vasculature is the release of tissue factor; Soejima
et al. [24] demonstrated that the administration of
ACE inhibitors signi®cantly affects plasma tissue
factor levels and, in an in vitro study, Nishimura et
al. showed that angiotensin II increases tissue factor
mRNA expression by cultured endothelial cells [25].
Recently, several reports demonstrate that throm-
bophilic polymorphisms are associated with an in-
creased risk of spontaneous fetal loss, and that the
combination of thrombophilic polymorphisms fur-
ther increases the risk of unexplained fetal loss [10].
In this study, the prevalence of FV Leiden mutation
in patients with a history of complicated pregnancy
is lower than that previously reported by other
studies and by ourselves [10,11,26]. This may be due
to the investigation of second- and third-trimester
fetal loss, whereas in this study we included only
®rst-trimester fetal loss. The lack of association of
FII G20210A mutation and fetal loss is in keeping
with previous studies [10,11]. However, given the
small size of the samples examined, the results
cannot be considered conclusive.
Finally, this study adds further weight to the role
of hyperhomocysteinemia in fetal loss, as suggested
by the Hordaland Homocysteine Study [27] and by
the association between MTHFR 677TT and preg-
nancy loss [10].
In conclusion, our results identify new possible
predictive markers for fetal loss in RAS gene
polymorphisms and in hyperhomocysteinemia.
Large-scale studies are warranted to attribute clinical
relevance to these polymorphisms as risk factors for
complicated pregnancies.
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